Vaxinano announces exclusive licensing agreement for canine Leishmaniasis vaccine with Vétoquinol

USA - English

• France - Français

LILLE, France, Nov. 12, 2024 /PRNewswire/ -- Today Vaxinano, a biotech company headquartered in Lille (France) announced an exclusive license agreement with Vetoquinol to develop its leading canine leishmaniasis vaccine candidate utilizing Vaxinano's proprietary nanoparticle technology.

The terms of the agreement were not disclosed but they include upfront and milestone payments as well as R&D funding to Vaxinano.

Canine leishmaniasis is an incurable multisystemic zoonosis caused by a parasite that leads to death in symptomatic dogs, affecting globally 100 million dogs. This parasite causes visceral, cutaneous, and mucosal leishmaniasis with a prevalence varying between 5-20% in the Mediterranean Basin, North Africa, South America, and West Asia, and expanding in the Northern Hemisphere due to travel and climate change.

Philippe Gruet, Vetoquinol CSO commented "we are excited to collaborate with Vaxinano and the proprietary nanoparticle-based vaccine technology developed by Vaxinano. Leishmaniasis remains an unmet need waiting for viable solutions that we hope to bring to the One Health market in the coming years".

Jonathan Stauber, Vaxinano CEO said: "We are proud to collaborate with a well-regarded animal health global player such as Vetoquinol to develop a solution to combat leishmaniasis, a climate change-linked and growingly expanding infection disease". Didier Betbeder, CSO said: "This collaboration reinforces the value of our technology for veterinary vaccines. The success in treating leishmaniasis further demonstrates the platform's effectiveness, including its potential for immunotherapy. These promising results pave the way for the development of a wide range of therapeutic vaccines."

About Vaxinano

Vaxinano develops nasal vaccines based on Stellar-NP, a unique vaccine delivery system designed to address unmet needs in infectious disease. It offers rapid, efficient and safe vaccines to protect animals and humans. The uniqueness of the technology lies in its adjuvant-free formulation and high stability, facilitating fast and easy global distribution. Within just three years, Vaxinano has developed versatile mucosal prophylactic or therapeutic vaccines against zoonosis (leishmaniasis, toxoplasmosis, colibacillosis, vibriosis), collaborating with top veterinary companies and international pharmaceutical companies. 

For more information, visit www.vaxinano.com and follow us on LinkedIn

Contact us : [email protected]

Logo: https://mma.prnewswire.com/media/2540538/5015874/Vaxinano_Logo.jpg

SOURCE Vaxinano